Stifel Financial Corp Sells 4,366 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Stifel Financial Corp lessened its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 25.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,807 shares of the company’s stock after selling 4,366 shares during the period. Stifel Financial Corp’s holdings in BeiGene were worth $2,875,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quantinno Capital Management LP bought a new position in shares of BeiGene in the third quarter worth $295,000. Point72 Asset Management L.P. grew its stake in BeiGene by 74.9% during the third quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock worth $149,785,000 after buying an additional 285,784 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in BeiGene in the 3rd quarter valued at about $67,000. Erste Asset Management GmbH acquired a new position in shares of BeiGene in the 3rd quarter valued at approximately $4,478,000. Finally, Bellevue Group AG lifted its holdings in shares of BeiGene by 129.2% during the 3rd quarter. Bellevue Group AG now owns 58,729 shares of the company’s stock worth $13,185,000 after acquiring an additional 33,100 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

BeiGene Stock Performance

NASDAQ BGNE opened at $179.06 on Wednesday. The company has a market capitalization of $17.45 billion, a price-to-earnings ratio of -21.64 and a beta of 0.57. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $248.16. The stock has a fifty day simple moving average of $205.89 and a 200 day simple moving average of $187.30. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same quarter last year, the business earned $2.01 earnings per share. BeiGene’s revenue was up 28.2% compared to the same quarter last year. Sell-side analysts expect that BeiGene, Ltd. will post -5.64 EPS for the current year.

Insiders Place Their Bets

In other news, insider Xiaodong Wang sold 41,760 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $186.90, for a total value of $7,804,944.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Xiaobin Wu sold 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total value of $900,630.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,136,122 shares of company stock worth $213,421,417. 7.43% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BGNE has been the topic of a number of recent analyst reports. StockNews.com cut shares of BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Morgan Stanley reissued an “overweight” rating and set a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. JMP Securities initiated coverage on BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective on the stock. TD Cowen lifted their price target on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $253.69.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.